How many stocks are there of Inventiva?
The current number of stocks of Inventiva is 45.35 M undefined.
Inventiva Stocks 2024
Inventiva Stocks
45.35 M
Inventiva Dividend yield
Ticker
IVA.PA
ISIN
FR0013233012
WKN
A2DLV9
In 2024, Inventiva had 45.35 M outstanding stocks, a 0% change from the 45.35 M stocks in the previous year.
The Inventiva Stocks history
| YEAR | NUMBER OF STOCKS (undefined EUR) |
|---|---|
| 2029e | 45.35 |
| 2028e | 45.35 |
| 2027e | 45.35 |
| 2026e | 45.35 |
| 2025e | 45.35 |
| 2024e | 45.35 |
| 2023 | 45.35 |
| 2022 | 41.45 |
| 2021 | 39.17 |
| 2020 | 33.87 |
| 2019 | 23.52 |
| 2018 | 20.54 |
| 2017 | 15.52 |
| 2016 | 10.03 |
| 2015 | 10.03 |
| 2014 | 10.03 |
| 2013 | 10.03 |
Inventiva Aktienanalyse
What does Inventiva do?
Inventiva SA is a biopharmaceutical company based in France that specializes in the development of novel therapies for various diseases. The company was founded in 2002 by Pierre Broqua and Frédéric Cren to develop innovative drugs based on research on the human genome. Inventiva's business model is to develop a pipeline of drug candidates and either sell them or bring them into partnerships with other companies. The company has built a broad portfolio of patents and license agreements that allow it to develop a variety of products. Inventiva's research and development focuses on three key areas: fibrosis, oncology, and autoimmune diseases. In these areas, the company has several product candidates in various stages of clinical development. Inventiva's products include Lanifibranor, a drug for the treatment of fatty liver disease, which is currently in Phase III trials. Additionally, the company has several compounds in its oncology pipeline, including IVA337, IVA336, and IVA339, all of which have shown promising results in preclinical studies. In the field of autoimmune diseases, Inventiva is working on a compound called ABBV-157, which is being developed in collaboration with Abbvie. This compound is intended to help reduce inflammation in patients with rheumatoid arthritis and psoriasis. Overall, Inventiva has made significant progress in recent years and has achieved important milestones in the development of its products. The company has also entered into several partnerships with major pharmaceutical and biotech companies to bring its products to market. In 2020, Inventiva took the next important step in its growth strategy by announcing a merger with American company AbbVie. The acquisition is expected to accelerate the development and commercialization of Inventiva's products and provide the company with a strong partner in the international market. However, Inventiva has not limited itself to drug development. The company has also developed a range of services to support other companies in the development of new drugs. These include laboratory services, protein purification and analysis, cell culture, and more, offered through their own contract research organization (CRO) unit. In summary, Inventiva is an emerging company with a strong portfolio of products and services. The company has done excellent work in developing new medical technologies in recent years and is likely to have even more success in the future with the acquisition by AbbVie. Inventiva ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Inventiva's Shares Outstanding
Inventiva's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Inventiva’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Inventiva’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Inventiva’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Inventiva Stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Inventiva are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Inventiva evolved in recent years?
The number of shares of Inventiva has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Inventiva as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Inventiva?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Inventiva pay?
Over the past 12 months, Inventiva paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inventiva is expected to pay a dividend of 0 EUR.
What is the dividend yield of Inventiva?
The current dividend yield of Inventiva is .
When does Inventiva pay dividends?
Inventiva pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Inventiva?
Inventiva paid dividends every year for the past 0 years.
What is the dividend of Inventiva?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Inventiva located?
Inventiva is assigned to the 'Health' sector.
Wann musste ich die Aktien von Inventiva kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Inventiva from 5/27/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/27/2024.
When did Inventiva pay the last dividend?
The last dividend was paid out on 5/27/2024.
What was the dividend of Inventiva in the year 2023?
In the year 2023, Inventiva distributed 0 EUR as dividends.
In which currency does Inventiva pay out the dividend?
The dividends of Inventiva are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Inventiva
Our stock analysis for Inventiva Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inventiva Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
